CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $5.58B, above the global median of $1.15B
- FinancialsAltman Z-Score 1.88: grey zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.15%Below 5Y avg (0.18%)
Annual Rate
INR 0.50Paid unknown
Payout Ratio
14.7%Sustainable
Last Ex-Dividend
Jul 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
529.81BINR5.58B · vs all stocks (USD)
Trailing P/E
95.71xvs Biotechnology peers
Revenue (TTM)
173.21BINR1.82B · vs all stocks (USD)
Profit Margin
2.86%vs Biotechnology peers
Beta
0.3180xvs all stocks
52-Week Change
-10.25%vs all stocks
Forward Annual Dividend Yield
0.15%vs all stocks
Market Capitalization
529.81BINR5.58B · vs all stocks (USD)
Enterprise Value
665.32BINR7.01B · vs all stocks (USD)
Trailing P/E
95.71xvs Biotechnology peers
Forward P/E
29.54xvs Biotechnology peers
PEG Ratio
0.4079xvs Biotechnology peers
Price to Sales (TTM)
3.06xvs Biotechnology peers
Price to Book (MRQ)
1.54xvs Biotechnology peers
Enterprise to Revenue
3.84xvs Biotechnology peers
Enterprise to EBITDA
18.57xvs Biotechnology peers
Gross Margin
65.80%vs Biotechnology peers
Profit Margin
2.86%vs Biotechnology peers
Operating Margin
6.91%vs Biotechnology peers
Return on Assets (TTM)
0.61%vs Biotechnology peers
Return on Equity (TTM)
1.05%vs Biotechnology peers
Revenue (TTM)
173.21BINR1.82B · vs all stocks (USD)
Revenue per Share (TTM)
117.85INRUpdated Oct 24, 2026Quarterly Revenue Growth
10.00%vs Biotechnology peers
Gross Profit (TTM)
105.98BINR1.12B · vs all stocks (USD)
EBITDA (TTM)
38.54BINR405.99M · vs all stocks (USD)
Net Income (TTM)
4.95BINR52.18M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
349.40%vs Biotechnology peers
Operating Cash Flow (TTM)
19.94BINR210.07M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
3.86BINR40.62M · vs all stocks (USD)
Forward Annual Dividend Rate
0.5000INRUpdated Oct 24, 2026Forward Annual Dividend Yield
0.15%vs all stocks
Trailing Annual Dividend Rate
0.00INRUpdated Oct 24, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
5-Year Average Dividend Yield
0.18%vs all stocks
Payout Ratio
14.71%vs Biotechnology peers
Minority Interest (Equity)
25.90BINRFY2026 · Mar 31, 2026Revenue
167.80BINRFY2026 · Mar 31, 2026Cost of Goods Sold
56.95BINRFY2026 · Mar 31, 2026Gross Profit
110.85BINRFY2026 · Mar 31, 2026Operating Income
17.22BINR181.42M · vs all stocks (USD)
Pre-tax Income
4.48BINRFY2026 · Mar 31, 2026Income Tax Expense
791.00MINRFY2026 · Mar 31, 2026Net Income
3.69BINRFY2026 · Mar 31, 2026EBIT
14.13BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
36.53BINRFY2026 · Mar 31, 2026Research & Development
7.08BINRFY2026 · Mar 31, 2026Selling, General & Administrative
13.73BINRFY2026 · Mar 31, 2026Other Operating Expenses
19.18BINRFY2026 · Mar 31, 2026Non-operating Interest Income
1.15BINRFY2026 · Mar 31, 2026Non-operating Interest Expense
9.65BINRFY2026 · Mar 31, 2026EPS (Basic)
2.82INRFY2026 · Mar 31, 2026EPS (Diluted)
2.82INRFY2026 · Mar 31, 2026Basic Shares Outstanding
1.37BSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
1.37BSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
3.69BINRFY2026 · Mar 31, 2026Minority Interests (P&L)
168.00MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
5.27BINRFY2026 · Mar 31, 2026Free Cash Flow
-12.71BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
21.11BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
3.69BINRFY2026 · Mar 31, 2026Stock-based Compensation
1.64BINRFY2026 · Mar 31, 2026Other Non-cash Items
9.35BINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
6.24BINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-15.65BINRFY2026 · Mar 31, 2026Capital Expenditures
-17.98BINRFY2026 · Mar 31, 2026Net Intangibles (CF)
-1.14BINRFY2026 · Mar 31, 2026Net Acquisitions
0.00INRFY2026 · Mar 31, 2026Purchase of Investments
-235.36BINRFY2026 · Mar 31, 2026Sale of Investments
232.17BINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-21.16BINRFY2026 · Mar 31, 2026Long-term Debt Issuance
2.66BINRFY2026 · Mar 31, 2026Long-term Debt Payments
-27.08BINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
349.00MINRFY2026 · Mar 31, 2026Common Stock Repurchase
-26.00MINRFY2026 · Mar 31, 2026Common Dividends Paid
-908.00MINRFY2026 · Mar 31, 2026Other Financing Charges
-59.65BINRFY2026 · Mar 31, 2026Net Financing Cash Flow
1.36BINRFY2026 · Mar 31, 2026Shares Outstanding
1.64BSharesUpdated Oct 24, 2026Float Shares
819.36MSharesUpdated Oct 24, 2026% Held by Insiders
48.18%vs all stocks
% Held by Institutions
32.03%vs all stocks
Total Cash (MRQ)
38.83BINR409.08M · vs all stocks (USD)
Total Cash per Share (MRQ)
23.98INRUpdated Oct 24, 2026Total Debt (MRQ)
154.34BINR1.63B · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4214xvs Biotechnology peers
Current Ratio (MRQ)
1.22xvs Biotechnology peers
Book Value per Share (MRQ)
210.14INRUpdated Oct 24, 2026Total Assets
636.51BINR6.71B · vs all stocks (USD)
Total Current Assets
171.80BINRFY2026 · Mar 31, 2026Total Liabilities
270.29BINRFY2026 · Mar 31, 2026Total Non-current Assets
464.71BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
129.60BINRFY2026 · Mar 31, 2026Total Current Liabilities
140.69BINRFY2026 · Mar 31, 2026Cash
11.05BINRFY2026 · Mar 31, 2026Cash Equivalents
13.11BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
24.16BINRFY2026 · Mar 31, 2026Other Short-term Investments
16.27BINRFY2026 · Mar 31, 2026Accounts Receivable
59.87BINRFY2026 · Mar 31, 2026Inventory
60.86BINRFY2026 · Mar 31, 2026Accounts Payable
67.72BINRFY2026 · Mar 31, 2026Short-term Debt
41.51BINRFY2026 · Mar 31, 2026Other Current Liabilities
388.00MINRFY2026 · Mar 31, 2026Long-term Debt
112.83BINRFY2026 · Mar 31, 2026Other Non-current Liabilities
5.55BINRFY2026 · Mar 31, 2026Common Stock (Book)
8.11BINRFY2026 · Mar 31, 2026Retained Earnings
139.92BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
366.21BINR3.86B · vs all stocks (USD)
Treasury Stock
423.00MINRFY2026 · Mar 31, 202652-Week Low
318.40INRUpdated Oct 24, 202652-Week High
447.15INRUpdated Oct 24, 202652-Week Change
-10.25%vs all stocks
Beta
0.3180xvs all stocks
50-Day MA
381.19INRUpdated Oct 24, 2026200-Day MA
391.46INRUpdated Oct 24, 2026Avg 10-Day Volume
2.51MSharesUpdated Oct 24, 2026Avg 30-Day Volume
2.81MSharesUpdated Oct 24, 2026Diluted EPS (TTM)
3.38INRUpdated Oct 24, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.66Profit Margin: 0.03
Financial Health
Altman Z-Score 1.88: grey zoneSignificant
Altman Z-Score: 1.88
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $5.58B, above the global median of $1.15BNotable
Market cap (USD): 5,581,584,263.509Global Median: 1,150,228,651.185
Revenue is $1.82B, above the global median of $560.37MNotable
Revenue (USD): 1,824,777,807.462Global Median: 560,374,939.3
Levered free cash flow is $40.62M, above the global median of $18.79MNotable
Levered free cash flow (USD): 40,622,960Global Median: 18,786,990.71
Companies that share the same coordination system — how they create, deliver, or capture value.
Oruka Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Travere Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cogent Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. A Shares
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
APT Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kiniksa Pharmaceuticals International, plc
Tier 1ProductionApproval-Gated PipelineRule
Mirum Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Salubris Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Scholar Rock Holding Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Crispr Therapeutics AG
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
SPIE SA
3 interpretationsMulti-Year Revenue, Profit, And Income GrowthClose Below 40W SMA With ProfitabilityPrice Below Mean With Profitability And Book Value
Vinci SA
3 interpretationsMulti-Year Revenue, Profit, And Income GrowthClose Below 40W SMA With ProfitabilityPrice Below Mean With Profitability And Book Value
Bwx Technologies Inc.
3 interpretationsMulti-Year Revenue, Profit, And Income GrowthClose Below 40W SMA With ProfitabilityPrice Below Mean With Profitability And Book Value